[Asialofetuin-hTERT-TK/GCV targeted gene therapy and its bystander effect on HepG2].
OBJECTIVE
To observe the targeted therapeutic effects of plasmid AF-pGL3-hTERT-TK on HepG2 cells.


METHODS
HepG2 cells were cultured and pGL3-hTERT-TK and AF-liposome were constructed. HepG2 and L02 cells were transfected with AF-pGL3-hTERT-TK. The growth, apoptosis of the cells and the bystander effects were studied using liquid scintillation analysis and tunnel and flow cytometry.


RESULTS
After the suicide gene was inserted into the downstream of hTERT, TK was effectively driven by the hTERT promoter, making the TK highly expressed in the HepG2 cells. The AF made the therapeutic gene enter the HepG2 cells more easily by recognizing and combining the ASGPR receptor protein on the HepG2 cell surfaces and induced their apoptosis and suicide with bystander effect. The apoptosis rate was 85%+/-3% in the HepG2 cells whereas in the normal L02 hepatic cells it was 16%+/-2%.


CONCLUSIONS
AF-pGL3-hTERT-TK can target and attack HepG2 cells and has almost no influence on normal L02 hepatic cells. AF-pGL3-hTERT-TK has a potential in the treatment of hepatocellular carcinomas.
Yang
Chang-qing
CQ
Department of Gastroenterology, Second Hospital of Shanxi Medical University, Taiyuan 030001, China.
Deng
Zhi-hua
ZH
Liu
Yan
Y
Liu
Jing-long
JL
Cao
Yan
Y
D017209:Apoptosis; D001212:Asialoglycoproteins; D024201:Bystander Effect; D060748:Fetuins; D015774:Ganciclovir / Q000378:metabolism; D041722:Genes, Transgenic, Suicide; D015316:Genetic Therapy; D056945:Hep G2 Cells; D006801:Humans; D019098:Telomerase / Q000378:metabolism*; D013937:Thymidine Kinase / Q000378:metabolism; D014162:Transfection; D000509:alpha-Fetoproteins
D001212:Asialoglycoproteins; D060748:Fetuins; D000509:alpha-Fetoproteins; C017029:asialofetuin; D013937:Thymidine Kinase; C509186:TERT protein, human; D019098:Telomerase; D015774:Ganciclovir